Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Promedior (Malvern, PA), a clinical-stage biotechnology company focused on Age-Related Macular Degeneration, closed a $3M Series D financing, bringing the total round to $24.5M. Participants include Shire Strategic Investment Group, Fibrotec Ventures, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. Collective IP | The Most Comprehensive and Accurate [...]

Aclaris Therapeutics (Malvern, PA), a preclinical-stage pharmaceutical company focused on topical dermatological therapies, closed a $21M Series A financing. Participants include Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Vascular Magnetics (Philadelphia, PA) a development-stage medical device focused on magnetically targeted drug delivery for the treatment of peripheral artery disease, closed a $7M Series A financing. Participants include Devon Park Bioventures. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Tarsa Therapeutics (Philadelphia, PA) a clinical-stage biopharmaceutical company focused on treatments for postmenopausal osteoporosis, closed a $28 Series B financing. Participants include Foresite Capital, Novo, MVM Life Science Partners and Quaker Partners.

Promedior (Malvern, PA) a clinical stage biotechnology company developing pentraxin therapeutics for fibroproliferative diseases, closed a $21.5M Series D financing. Participants include Fibrotec Ventures, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group.

Azelon Pharmaceuticals (West Conshohocken, PA) a preclinical-stage pharmaceutical company focused on osteoporosis, closed a $4.5M Series A financing. Participants include Prospect Venture Partners, Lighthouse Capital Partners and Covington Venture Fund.

Intimate Bridge 2 Conception (Pittsburgh, PA) a clinical-stage medical device company focused on fertility and reproductive health, closed a $5M Series financing. Participants include PLSG Accelerator Fund.

Cohera Medical (Pittsburgh, PA) a commercial-stage biotechnology company focused on wound management, mesh fixation and surgical tissue adhesives, closed a $25M Series C financing. Participants include Kern Whelan Capital.

Ceptaris Therapeutics (Malvern, PA) a clinical-stage specialty pharmaceutical company focused on the treatment of mycosis fungoides, a type of cutaneous t-cell lymphoma, closed a $14.4M Series D financing. Participants include Vivo Ventures, Palo Alto Investors, Burrill & Co. and Aperture Venture Partners. Thanx for your patience as we catch-up.

ProtonMedia (Landsdale, PA) a commercial-stage cloud-based life science product lifecycle project management platform, closed a $4.5M Series B financing. Participants include Kaplan Ventures. The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach >45,000 high-value targeted life science professionals on-line and in-print. Contact arubenstein@rnaventures.com for details.

Neuronetics (Malvern, PA) a commercial-stage medical device company focused on pulsed magnetic field stimulation for non-invasive, non-systemic treatment of depression, closed a $30M Series E financing. Participants include Polaris Venture Partners, Pfizer Venture Investments, Investor Growth Capital, New Leaf Venture Partners, Interwest Partners, Three Arch Partners, Quaker BioVentures and Onset Ventures.

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage pharmaceutical company developing novel small molecule drugs to treat cancer, closed a $6M Series C financing bringing the total round to $43M. Participants include Nextech Invest, Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, Vertical Group and Amgen Ventures.

Carmell Therapeutics (Pittsburgh, PA) a development-stage biopharmaceutical company focused on biomaterials for connective tissue repair, closed a $2.4M Series A financing. Participants include Harbor Light Capital Partners, Newlin Investment Company, PLSG Accelerator Fund, Innovation Works, Ariel Savannah Angels and Blue Tree Allied Angels.

« Previous Entries  Next Page »

to top of page...